Track: Cancer Research Therapy and Autoimmune Diseases

Cancer Research Therapy and Autoimmune diseases

The "Cancer Research Therapy and Autoimmune Diseases" session will focus on the intersection of cancer research and autoimmune disorders, exploring how advances in cancer therapies can influence autoimmune conditions, and vice versa. 

Recent research has revealed intriguing connections between cancer and autoimmune diseases. In both cases, the immune system plays a critical role, either failing to prevent cancer or mistakenly attacking the body’s own tissues in autoimmune diseases. This session will examine how breakthroughs in cancer therapies influence autoimmune conditions and delve into the biological pathways that overlap between these conditions, highlighting how understanding these links can lead to innovative treatment approaches.

Key Topics Covered
This session will address several crucial areas including

Cancer Research and Chemotherapy: Examining the latest developments in chemotherapy and how they impact patients with co-existing autoimmune conditions.

Advancements in Cancer Therapy: Reviewing the progress in targeted therapies and personalized medicine, focusing on how these approaches can be adapted for patients with autoimmune diseases.

Immunosuppressants: Understanding the role of immunosuppressive drugs in managing autoimmune conditions and how they might affect cancer treatment and progression.

Autoimmune Responses in Cancer Patients: Exploring the delicate balance between activating the immune system to fight cancer and preventing unwanted autoimmune reactions.

Checkpoint Inhibitors: Discussing how immune checkpoint inhibitors, a powerful tool in cancer immunotherapy, can trigger autoimmune side effects and strategies to manage these complications.

CAR T-Cell Therapy: Analyzing the use of CAR T-cell therapy in cancer treatment, including its potential to induce or worsen autoimmune conditions and ongoing research to mitigate these effects.

Targeted Treatments: Highlighting the latest targeted therapies that specifically address the unique challenges of treating cancer in patients with autoimmune diseases.